// App-Quantinova.ai

TPS4603 : CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).

Researchers

Presenter

  • Guillermo de Velasco

Principal Investigators

  • Borja Gonz Alez

  • Teresa Alonso

  • Alvaro Pinto

  • Juan Francisco Rodriguez-Moreno

  • Juan Manuel Sepulveda

  • Jose Carlos Villa

  • Natalia Miranda

  • Felix Guerrero

  • Daniel E. Castellano

Medical Centers

  • Department of Medical Oncology, University Hospital 12 de Octubre, i + 12, Madrid, Spain., Madrid, Spain

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Hospital Ramon y Cajal, Madrid, Spain

  • Hospital Universitario La Paz, Madrid, Spain

  • Hospital Universitario Sanchinarro, Madrid, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • University General Hospital Ciudad Real, Ciudad Real, Spain

  • Hospital Doce de Octubre, Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • AXL receptor tyrosine kinase

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved